Predictive factors of THR in painful hip OA: univariate analysis
| THR (n = 189) | No THR (n = 316) | p Value | |
|---|---|---|---|
| Except where otherwise indicated, values are the mean (SD). | |||
| VAS, visual analogue scale; NSAIDs, non-steroidal anti-inflammatory drugs. | |||
| *Mean values of symptomatic outcome variables over the first 6 months were obtained for 448 patients and were dichotomised according to the median value. | |||
| Age (years) | 65.0 (9.8) | 63.4 (10.3) | 0.09 |
| Sex, No (%) female | 119 (63.0) | 190 (60.1) | 0.53 |
| Body mass index (kg/m2) | 26.3 (3.9) | 26.1 (3.9) | 0.55 |
| Duration of symptoms (years) | 4.4 (4.7) | 4.9 (5.5) | 0.28 |
| Location of hip OA, No (%) | |||
| Superolateral | 117 (61.9) | 189 (59.8) | 0.64 |
| Superomedial | 30 (15.9) | 59 (18.7) | 0.42 |
| Global | 52 (27.5) | 79 (25.0) | 0.53 |
| OA in contralateral hip, No (%) | 68/184 (37.0) | 128/305 (42.0) | 0.27 |
| Radiological grade (Kellgren-Lawrence), No (%) | <0.0001 | ||
| III | 101 (53.4) | 172 (54.4) | |
| IV | 73 (38.6) | 69 (21.8) | |
| Previous treatment, No (%) | |||
| NSAIDs | 139 (73.5) | 191 (60.4) | 0.003 |
| Hip intra-articular injections | 8 (4.2) | 12 (3.8) | 0.81 |
| Baseline pain (0–100 mm VAS) | 57.0 (16.2) | 53.8 (15.4) | 0.03 |
| Baseline WOMAC function score (0–100) | 45.7 (15.9) | 43.7 (16.3) | 0.17 |
| Baseline patient global assessment (0–100 mm VAS) | 60.7 (19.1) | 56.1 (17.7) | 0.006 |
| Mean pain over the first 6 months >42 (0–100 mm VAS), No (%)* | 282 (62.9) | 189 (42.2) | <0.0001 |
| Mean WOMAC function score over the first 6 months >26 (0–100 mm VAS), No (%) * | 268 (59.8) | 197 (44.0) | 0.001 |
| Mean patient global assessment over the first 6 months >47 (0–100 mm VAS), No (%)* | 282 (62.9) | 189 (42.2) | <0.0001 |